Menlo Therapeutics reports positive data from Phase 2 acne vulgaris trial

Menlo Therapeutics Logo

Menlo Therapeutics (NASDAQ:MNLO) reported positive results from its Phase 2 trial evaluating FCD105 or the treatment of moderate-to-severe acne vulgaris.

The study enrolled 447 patients who received either FCD105, a 3% minocycline/0.3% adapalene foam; 3% minocycline foam; 0.3% adapalene foam; or vehicle. 

The majority of comparisons between FCD105 and either 3% minocycline foam or 0.3% adapalene foam demonstrated a statistically significant improvement at week 12 in patients receiving FCD105.

Patients who received FCD105 achieved Investigator’s Global Assessment treatment success of 36%, compared with 15.7% of patients in the vehicle group. Absolute reduction in inflammatory lesion counts at week 12 was -64% for the FCD105 treatment group, compared with -51% in the vehicle group.

“The data suggest FCD105 has the potential to be a best-in-class treatment for patients with acne and could provide an important new treatment option for this challenging condition,” Iain Stuart, Menlo’s CSO, said in a statement.

The company plans to conduct an end-of-Phase 2 meeting with the FDA before the end of this year.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.